Is Allergy Shots Safe for You? A Personal Risk Assessment Guide

The 2011 AAAAI/ACAAI Practice Parameter defines FEV1 below 70% of predicted as a threshold at which allergy shot injections should be deferred on that specific day. In clinical practice, many allergist offices measure peak expiratory flow before each injection for asthmatic patients — if your peak flow is below the threshold established for you, the injection is postponed. Signs that your asthma is not well enough controlled include needing your rescue inhaler more than twice per week, frequent nighttime awakenings from asthma symptoms, recent ER visits or oral steroid courses for exacerbations, or general worsening of breathing over recent weeks. Before starting SCIT, discuss your asthma control with your treating physician — optimizing inhaled corticosteroid therapy first, if needed, may be the right preparation step.

It depends on which blood pressure medication. Beta-blockers (metoprolol, atenolol, propranolol, carvedilol, bisoprolol, and others) are classified as a relative contraindication for SCIT because they impair the epinephrine response during anaphylaxis. However, relative contraindication means the decision requires shared decision-making, not automatic exclusion. For patients with compelling cardiac indications for beta-blockers, many allergists will proceed with appropriate precautions and the understanding that glucagon — not epinephrine alone — may be needed in an emergency. ACE inhibitors (lisinopril, enalapril, and others) are not contraindicated but warrant discussion, as bradykinin accumulation may potentiate anaphylaxis severity. Calcium channel blockers, diuretics, and ARBs do not carry the same concerns as beta-blockers. Disclose your complete medication list before starting.

Allergy shots are generally safe and effective for children ages 5 and older according to the 2011 AAAAI/ACAAI Practice Parameter. There is no evidence that pediatric patients face higher systemic reaction rates than adults in surveillance data. In fact, allergy shots in childhood carry an additional long-term benefit: the PAT study's 10-year follow-up (Jacobsen 2007, Allergy) found that children who received SCIT had a dramatically lower rate of asthma development — 25% vs. 45% in untreated controls. Younger children require age-appropriate assessment of asthma control and the ability to communicate early warning symptoms of a reaction, which requires clinical staff awareness during the observation period. The same risk factors apply to children as adults — asthma control is paramount — but the procedure itself is appropriate for school-age children.

Five questions are essential before your first injection. First: 'Based on my allergy test results, which allergens will be in my extract, and am I a good candidate for immunotherapy?' This confirms appropriateness. Second: 'I have [asthma / beta-blocker / prior reaction / other risk factor] — how does that change my protocol?' This ensures your risk factors are addressed. Third: 'What is your dose adjustment protocol for new vials and peak pollen season?' This confirms the practice follows evidence-based safety procedures. Fourth: 'What are the early warning signs I need to recognize, and what do I do if symptoms develop after I've left your office?' This prepares you for the 15% of systemic reactions that occur after the 30-minute window. Fifth: 'Do you carry epinephrine on site and have staff trained to use it?' This confirms the minimum safety infrastructure is in place.

There is no established upper age limit for allergy shots. A growing body of evidence supports the safety and efficacy of SCIT in elderly patients. Bozek 2023 (Curr Opin Allergy Clin Immunol) confirmed high safety of allergen immunotherapy in patients over 60 for grass pollen, birch pollen, and house dust mites. The practical considerations for older patients include a higher prevalence of cardiovascular comorbidities, more common beta-blocker and ACE inhibitor use, and greater polypharmacy in general — all of which require careful pre-treatment assessment rather than automatic exclusion. Cardiovascular disease does not contraindicate SCIT but means that if anaphylaxis occurs, the consequence may be more severe. The youngest appropriate age is 5, per the 2011 Practice Parameter, based on the ability to tolerate injections and cooperate with observation requirements.

A 30-minute observation period after each injection exists precisely because about 85% of systemic reactions begin within that window. With at-home SCIT through Curex you observe yourself for 30 minutes with a prescribed epinephrine auto-injector on hand, and your first dose and every dose change are supervised live over Zoom so your allergist can respond immediately. If you experience any symptoms — generalized itching, hives, throat tightness, wheezing, dizziness, or abdominal cramping — act promptly rather than waiting to see if they resolve. Reactions are graded on the WAO scale: Grade 1 mild reactions may be managed with antihistamines and extended observation; Grade 2-3 reactions require epinephrine; Grade 4 anaphylaxis requires epinephrine, 911, and hospital transport. The critical action on your part is to speak up and treat promptly — do not minimize symptoms during the observation window. Early treatment dramatically improves outcomes, and delayed epinephrine is consistently identified in fatality analyses as the most consequential management failure.